-
Abraham J, Corbett KD, Farzan M, Choe H, Harrison SC, 2010: Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses[J]. Nat Struct Mol Biol, 17, 438-444. doi: 10.1038/nsmb.1772
-
Baize S, Marianneau P, Loth P, Reynard S, Journeaux A, Chevallier M, Tordo N, Deubel V, Contamin H, 2009: Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys[J]. J Virol, 83, 5890-5903. doi: 10.1128/JVI.01948-08
-
Bonhomme CJ, Capul AA, Lauron EJ, Bederka LH, Knopp KA, Buchmeier MJ, 2011: Glycosylation modulates arenavirus glycoprotein expression and function[J]. Virology, 409, 223-233. doi: 10.1016/j.virol.2010.10.011
-
Bonhomme CJ, Knopp KA, Bederka LH, Angelini MM, Buchmeier MJ, 2013: LCMV glycosylation modulates viral fitness and cell tropism[J]. PLoS ONE, 8, e53273-. doi: 10.1371/journal.pone.0053273
-
Botten J, Alexander J, Pasquetto V, Sidney J, Barrowman P, Ting J, Peters B, Southwood S, Stewart B, Rodriguez-Carreno MP, Mothe B, Whitton JL, Sette A, Buchmeier MJ, 2006: Identification of protective Lassa virus epitopes that are restricted by HLA-A2[J]. J Virol, 80, 8351-8361. doi: 10.1128/JVI.00896-06
-
Bowden TA, Crispin M, Graham SC, Harvey DJ, Grimes JM, Jones EY, Stuart DI, 2009: Unusual molecular architecture of the machupo virus attachment glycoprotein[J]. J Virol, 83, 8259-8265. doi: 10.1128/JVI.00761-09
-
Cohen-Dvashi H, Cohen N, Israeli H, Diskin R, 2015: Molecular mechanism for LAMP1 recognition by Lassa virus[J]. J Virol, 89, 7584-7592. doi: 10.1128/JVI.00651-15
-
Eichler R, Lenz O, Garten W, Strecker T, 2006: The role of single N-glycans in proteolytic processing and cell surface transport of the Lassa virus glycoprotein GP-C[J]. Virol J, 3, 41-. doi: 10.1186/1743-422X-3-41
-
Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB, 2000: Effective vaccine for lassa fever[J]. J Virol, 74, 6777-6783. doi: 10.1128/JVI.74.15.6777-6783.2000
-
Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, Grolla A, Stroher U, Fernando L, Daddario KM, Guttieri MC, Mothe BR, Larsen T, Hensley LE, Jahrling PB, Feldmann H, 2005: Development of a new vaccine for the prevention of Lassa fever[J]. PLoS Med, 2, e183-. doi: 10.1371/journal.pmed.0020183
-
Gunther S, Emmerich P, Laue T, Kuhle O, Asper M, Jung A, Grewing T, ter Meulen J, Schmitz H, 2000: Imported lassa fever in Germany: molecular characterization of a new Lassa virus strain[J]. Emerg Infect Dis, 6, 466-476. doi: 10.3201/eid0605.000504
-
Hastie KM, Zandonatti MA, Kleinfelter LM, Heinrich ML, Rowland MM, Chandran K, Branco LM, Robinson JE, Garry RF, Saphire EO, 2017: Structural basis for antibody-mediated neutralization of Lassa virus[J]. Science, 356, 923-928. doi: 10.1126/science.aam7260
-
Hastie KM, Cross RW, Harkins SS, Zandonatti MA, Koval AP, Heinrich ML, Rowland MM, Robinson JE, Geisbert TW, Garry RF, Branco LM, Saphire EO, 2019: Convergent structures illuminate features for Germline antibody binding and pan-Lassa virus neutralization[J]. Cell, 178, e1014-.
-
Houlihan C, Behrens R, 2017: Lassa fever[J]. BMJ, 358, j2986-.
-
Ibukun FI, 2020: Inter-lineage variation of Lassa virus glycoprotein epitopes: a challenge to Lassa virus vaccine development[J]. Viruses, 12, 386-. doi: 10.3390/v12040386
-
Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, King IJ, 1987: Clinical virology of Lassa fever in hospitalized patients[J]. J Infect Dis, 155, 456-464. doi: 10.1093/infdis/155.3.456
-
McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R, 1986: Lassa fever[J]. Effective therapy with ribavirin. N Engl J Med, 314, 20-26.
-
Mire CE, Cross RW, Geisbert JB, Borisevich V, Agans KN, Deer DJ, Heinrich ML, Rowland MM, Goba A, Momoh M, Boisen ML, Grant DS, Fullah M, Khan SH, Fenton KA, Robinson JE, Branco LM, Garry RF, Geisbert TW, 2017: Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever[J]. Nat Med, 23, 1146-1149. doi: 10.1038/nm.4396
-
Robinson JE, Hastie KM, Cross RW, Yenni RE, Elliott DH, Rouelle JA, Kannadka CB, Smira AA, Garry CE, Bradley BT, Yu H, Shaffer JG, Boisen ML, Hartnett JN, Zandonatti MA, Rowland MM, Heinrich ML, Martinez-Sobrido L, Cheng B, de la Torre JC, Andersen KG, Goba A, Momoh M, Fullah M, Gbakie M, Kanneh L, Koroma VJ, Fonnie R, Jalloh SC, Kargbo B, Vandi MA, Gbetuwa M, Ikponmwosa O, Asogun DA, Okokhere PO, Follarin OA, Schieffelin JS, Pitts KR, Geisbert JB, Kulakoski PC, Wilson RB, Happi CT, Sabeti PC, Gevao SM, Khan SH, Grant DS, Geisbert TW, Saphire EO, Branco LM, Garry RF, 2016: Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits[J]. Nat Commun, 7, 11544-. doi: 10.1038/ncomms11544
-
Sommerstein R, Flatz L, Remy MM, Malinge P, Magistrelli G, Fischer N, Sahin M, Bergthaler A, Igonet S, Ter Meulen J, Rigo D, Meda P, Rabah N, Coutard B, Bowden TA, Lambert PH, Siegrist CA, Pinschewer DD, 2015: Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection[J]. PLoS Pathog, 11, e1005276-. doi: 10.1371/journal.ppat.1005276
-
ter Meulen J, Badusche M, Kuhnt K, Doetze A, Satoguina J, Marti T, Loeliger C, Koulemou K, Koivogui L, Schmitz H, Fleischer B, Hoerauf A, 2000: Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein[J]. J Virol, 74, 2186-2192. doi: 10.1128/JVI.74.5.2186-2192.2000
-
ter Meulen J, Badusche M, Satoguina J, Strecker T, Lenz O, Loeliger C, Sakho M, Koulemou K, Koivogui L, Hoerauf A, 2004: Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones[J]. Virology, 321, 134-143. doi: 10.1016/j.virol.2003.12.013
-
Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, Wheeler DK, Sette A, Peters B, 2019: The immune epitope database (IEDB): 2018 update[J]. Nucl Acids Res, 47, D339-D343. doi: 10.1093/nar/gky1006
-
Wang P, Liu Y, Zhang G, Wang S, Guo J, Cao J, Jia X, Zhang L, Xiao G, Wang W, 2018: Screening and identification of Lassa virus entry inhibitors from an FDA-approved drugs library[J]. J Virol, 92, e00954-e1918.
-
Warner BM, Safronetz D, Stein DR, 2018: Current research for a vaccine against Lassa hemorrhagic fever virus[J]. Drug Des Devel Ther, 12, 2519-2527. doi: 10.2147/DDDT.S147276
-
Watanabe Y, Raghwani J, Allen JD, Seabright GE, Li S, Moser F, Huiskonen JT, Strecker T, Bowden TA, Crispin M, 2018: Structure of the Lassa virus glycan shield provides a model for immunological resistance[J]. Proc Natl Acad Sci USA, 115, 7320-7325. doi: 10.1073/pnas.1803990115